Status:

ACTIVE_NOT_RECRUITING

A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

Lead Sponsor:

Chugai Pharmaceutical

Conditions:

Locally Advanced or Metastatic Solid Tumors

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

Phase I, open-label, multi-center study

Eligibility Criteria

Inclusion

  • (Both Part I and Part II)
  • Age \>= 18 years at time of signing informed consent form
  • ECOG performance status of 0 or 1
  • Patients with a locally advanced, recurrent, or metastatic solid tumor for which standard therapy either does not exist or has proven ineffective or intolerable
  • (Part I only)
  • Patients with measurable and/or evaluable disease per RECIST v1.1
  • Patients with MAPK pathway alterations positive solid tumor (i.e., BRAF, K/N/H-RAS mutations)
  • (Part II only)
  • Patients with measurable disease per RECIST v1.1
  • Patients with KRAS mutated NSCLC (NSCLC cohort)
  • Patients with KRAS mutated Ovarian Cancer (Ovarian Cancer cohort)
  • Patients with RAS mutated solid tumor (Biopsy cohort)

Exclusion

  • (Both Part I and Part II)
  • Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), unstable angina, or myocardial infarction within the previous 6 months or unstable arrhythmias within the previous 3 months
  • Patients with primary central nervous system (CNS) malignancy, untreated CNS metastases requiring any anti-tumor treatment, or active CNS metastases
  • Patients with current severe, uncontrolled systemic disease (including, but not limited to, clinically significant cardiovascular disease, pulmonary disease, or renal disease, ongoing or active infection)
  • Patients with a history or complication of interstitial lung disease (ILD)

Key Trial Info

Start Date :

September 10 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 30 2026

Estimated Enrollment :

113 Patients enrolled

Trial Details

Trial ID

NCT04511845

Start Date

September 10 2020

End Date

September 30 2026

Last Update

July 14 2025

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

Arizona Oncology

Tucson, Arizona, United States, 85711

2

Rocky Mountain Cancer Centers

Lone Tree, Colorado, United States, 80124

3

Minnesota Oncology

Minneapolis, Minnesota, United States, 55404

4

Rhode Island Hospital

Providence, Rhode Island, United States, 02903